MTOR and Hyponatremia: In the axitinib group (n = 52), patients discontinued treatment due to gastrointestinal perforation, renal dysfunction, perianal abscess, diarrhoea, hyponatremia, and hoarseness, whereas patients discontinued treatment due to dermatitis, stomatitis, and skin rash in the mTOR inhibitor group (n = 31) [38].